Salute e Benessere
Novo Nordisk A/S - share repurchase programme
– On 11 November 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 20 billion to be executed during a 12-month period beginning 6 February 2024.
Under the programme initiated 11 November 2024, Novo Nordisk will repurchase B shares for an amount up to DKK 3,136,206,122.30 in the period from 11 November 2024 to 3 February 2025.
Since the announcement 2 December 2024, the following transactions have been made:
The details for each transaction made under the share repurchase programme are published on novonordisk.com.
With the transactions stated above, Novo Nordisk owns a total of 22,962,636 B shares of DKK 0.10 as treasury shares, corresponding to 0.5% of the share capital. The total amount of A and B shares in the company is 4,465,000,000 including treasury shares.
Novo Nordisk expects to repurchase B shares for an amount up to DKK 20 billion during a 12-month period beginning 6 February 2024. As of 6 December 2024, Novo Nordisk has since 6 February 2024 repurchased a total 21,818,078 B shares at an average share price of DKK 828.33 per B share equal to a transaction value of DKK 18,072,465,051.
Company announcement No 94 / 2024
Attachments
2321 Rosecrans Avenue. Suite 2200
90245 El Segundo Stati Uniti